APA (7th ed.) Citation

H, T., N, Y., K, A., & P, E. (2026). Post-marketing safety signals of Wilson's disease therapies: Evidence from FAERS and VigiBase. Orphanet journal of rare diseases, 21(1), . https://doi.org/10.1186/s13023-026-04310-9

Chicago Style (17th ed.) Citation

H, Tezel-Yalçın, Yalçın N, Allegaert K, and Erkekoğlu P. "Post-marketing Safety Signals of Wilson's Disease Therapies: Evidence from FAERS and VigiBase." Orphanet Journal of Rare Diseases 21, no. 1 (2026). https://doi.org/10.1186/s13023-026-04310-9.

MLA (9th ed.) Citation

H, Tezel-Yalçın, et al. "Post-marketing Safety Signals of Wilson's Disease Therapies: Evidence from FAERS and VigiBase." Orphanet Journal of Rare Diseases, vol. 21, no. 1, 2026, https://doi.org/10.1186/s13023-026-04310-9.